Blocking rhinoviral adhesion molecule (ICAM-1): potential to prevent COPD exacerbations
Shakti Dhar Shukla,1–3 Philip Michael Hansbro,1–3 Eugene Haydn Walters4
1Priority Research Centre for Healthy Lungs, 2School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, NSW, Australia; 3Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; 4School of Medicine, University of Tasmania, Hobart, TAS, Australia
Acute exacerbations of COPD (AECOPD) are markers of disease progression and severity, and frequently are used as an outcome variable in interventional studies.1 AECOPD results in increased severity of symptoms and induces disease progression with accelerated decline in lung function and decreased quality of life. The risk of morbidity and mortality is also significantly increased. Most AECOPD (~85%) have an infectious etiology, induced by bacteria and viruses, often rhinovirus (~50%).1
View the original paper by Johnston and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]